Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston gets exclusive paclitaxel rights:

This article was originally published in Clinica

Executive Summary

Boston Scientific has signed an agreement with Natural Pharmaceuticals to allow the device maker exclusive use of the drug paclitaxel in a range of medical devices. As part of the deal, Boston invested an undisclosed amount of money in the Beverly, Massachusetts-based company. Boston is developing a polymer-based paclitaxel eluting stent and it says that the drug showed "promising results in preclinical studies". The privately owned Natural has access to several million ornamental yew trees, a prime source of the drug.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT072606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel